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267A. Fatima et al. / Stem Cell Research 17 (2016) 266–272pluripotent stem cell (miPSC) line TiB7.4 (Meissner et al., 2007) to ob-
tain the transgenic line αPIG-AT25 by transfecting the cells with the
plasmid expressingpuromycinN-acetyltransferase (PAC) and enhanced
green ﬂuorescent protein (EGFP) under the control of the CM-speciﬁc
α-myosin heavy chain (α-MHC) promoter (Fig. 1A). The αPIG-AT25
miPSCs exhibit pluripotent stem cell colony morphology (Fig. 1B) and
express alkaline phosphatase (Fig. 1C), the self-renewal protein Oct4
(Fig. 1D) and pluripotent stem cell marker SSEA1 (Fig. 1E). The promot-
er regions of Nanog and Oct4 genes are similarly hypomethylated in
αPIG-AT25 iPSCs and transgenic murine embryonic stem cells (ESC)
line αPIG44 that was generated previously using the same vector
(Kolossov et al., 2006) (Fig. 1F). In contrast, the same promoter regions
were highly methylated in tail tip ﬁbroblasts (TTF), from which the
iPSCs were generated, and in αPIG-AT25 miPSC-derived CMs (Fig. 1F).
The transgenic iPSCs differentiate into embryoid bodies (EBs) con-
taining spontaneously beating EGFP-positive areas, which ﬁrst appear
on day 7–9 of differentiation (Fig. 2A). After 7 days of puromycin treat-
ment, nearly all non-cardiomyocytes in EBs are eliminated and the re-
sistant cells survive as spontaneously beating EGFP-positive clusters
(Fig. 2A). Flow cytometric analyses of clusters dissociated into single
cells revealed that these clusters are enriched in CMs up to 97% (Fig.
2C) and that all EGFP-positive cells are uniformly stained for cardiac tro-
ponin T (cTnT) (Fig. 2D). When plated on ﬁbronectin-coated plates,
these CMs grow as a monolayer of spontaneously contracting CMs
(Fig. 2B) which express cardiac proteins troponin T, α-MHC and α-
actinin (Fig. 2E) and exhibit immature cross-striation pattern (Fig. 2F).
Semi-quantitative RT-PCR analyses showed that cardiac transcripts
Mef2c, GATA4, NKx2.5, TnnC, TnnT and RyR2 as well as transgenic PAC
are enriched in αPIG-AT25-iPSC- and αPIG44-ESC-derived CMs com-
pared to undifferentiated cells and intact EBs (Fig. 3A). In contrast, the
transcripts formesodermal (ε-globin) and endodermalmarkersα-feto-
protein (Afp), Sox17 and CD31were not detected (Fig. 3A). As expected,
virally encoded transcripts were not detectable in ESCs. However, they
are expressed at low levels in undifferentiated iPSCs and iPSC-derived
EBs but not in puriﬁed iPSC-derived CMs with the exception of
retrovirally encoded Oct4 that appears to be incompletely silenced in
CMs (Fig. 3B). Quantitative RT-PCR analyses also demonstrated thatFig. 1. Generation and characterization of transgenic murine αPiG-AT25 iPSC line. A. Themap o
vector, theα-myosin heavy chain (α-MHC) promoter drives the expression of puromycinN-ace
plasmid also encodes for a neomycin resistance (neor) gene amino 3-glycosyl phosphotrans
undifferentiated iPSCs growing on irradiated MEFs. C. Alkaline phosphate staining of iPS
counterstained with Hoechst 33,342. E. Flow cytometric analysis of SSEA1 expression on undif
(TTF) used for generation of iPSCs, undifferentiated (UD) transgenic αPiG-AT25 iPSCs and αPiCMs are highly enriched in transcripts encoding for transcription factor
Nkx2.5 and structural proteins cardiac ventricular myosin light chain 2
(Myl2) and α heavy chain subunit of cardiac myosin (Myh6) as well as
in transcripts encoding for the vector-derived EGFP (Fig. 3C). These
analyses also show that CMs express no or very low levels of
pluripotency-associated transcripts for Nanog and Oct4 as well as endo-
derm-speciﬁc mRNAs for Afp and Sox17 (Fig. 3C).
Action potentials (APs) of spontaneously beating αPIG-AT25-iPSC-
derived CMs exhibit a variety of morphologies, including pacemaker-
like, atrial-like, and ventricular-like APs (Fig. 4A). However, most APs
could not be further speciﬁed. The whole-cell current-clamp measure-
ments revealed the existence of intact β-adrenergic and muscarinic
signalling cascades in lineage-selected CMs as demonstrated by
the response to β-adrenergic receptor agonist isoproterenol (Iso)
and muscarinic receptor agonist carbachol (CCh), which was similar
to that of previously reported murine iPSC-derived CMs (Fig. 4B–D)
(Kuzmenkin et al., 2009; Nembo et al., 2015; Pfannkuche et al.,
2009). Puriﬁed iPSC-derived CMs expressed functional voltage-
gated Na+-, L-type Ca2+- and K+-channels with current densities
that were comparable to that of iPSC-derived CMs reported previously
(Kuzmenkin et al., 2009) (Fig. 5A–D). The contribution of different
K+-channels to the net depolarization-activated outward K+-current
was similar in drug-selected iPSC- and ESC-derived CMs. The current-
voltage relationships of all currents were also indistinguishable be-
tween iPSC- and ESC-derived CMs (Fig. 5E).
Materials and methods
iPSC culture
This miPSC line was maintained on irradiated mouse embryonic ﬁ-
broblasts (MEF) inDulbecco'sModiﬁed Eagle'sMedium(Gibco) supple-
mented with 15% fetal bovine serum (FBS), 1× non essential amino
acids, 2 mM L-glutamine, 50 μM 2-mercaptoethanol, and 1000 U/ml
Leukemia Inhibitory Factor (LIF; ESGRO, Chemicon International). The
cells were passaged regularly at 2–3 day interval by 0.05% trypsin/
EDTA dissociation.f theα-MHC–PAC–IRES–EGFP (αPIG) vector used for genetic modiﬁcation of iPSCs. In this
tyltransferase (PAC) and the IRES-ﬂanked enhanced green ﬂuorescent protein (EGFP). The
ferase which is controlled by a constitutive SV40 promoter. B. Phase contrast images of
C colonies. D. Detection of Oct4 expression by immunocytochemistry. Nuclei were
ferentiated iPSCs. F. Methylation status of Oct4 and Nanog promoters in tail tip ﬁbroblasts
G44 ESCs and in puromycin-selected CMs derived from them.
Fig. 2. Generation of CMs from transgenic iPSCs by puromycin selection. Intact αPiG-AT25 iPSC-derived EBs at day 9 of differentiation without exposure to puromycin exhibiting EGFP-
positive areas (left panel). Pure cardiac clusters obtained after 7 days of puromycin treatment are shown in the right (EGFP-channel) panel. B. Enzymatically dissociated drug-selected
CMs grow as a monolayer of EGFP-positive cells on ﬁbronectin-coated tissue culture plates. C. Flow cytometric analysis of the frequency of EGFP-positive CMs in dissociated cardiac
clusters at day 16 of differentiation without (left panel) and with (right panel) puromycin treatment for seven days. D. Flow cytometry reveals co-expression of cardiac troponin T
with EGFP in puromycin selected CMs stained with isotype control antibody (left panel) and anti-troponin T (right panel). E. Immunocytochemical stainings of plated transgenic iPSC-
derived CMs with anti-troponin T, anti-α-MHC and anti-sarcomeric α-actinin. Scale bars: 50 μm. F. Confocal ﬂuorescence microscopy of puriﬁed αPiG-AT25 iPSC-derived CMs at large
magniﬁcation indicates cell morphology and sarcomeric structures resembling immature CMs. Nuclei in panels B, E and F were counterstained with Hoechst 33342.
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The α-MHC–PAC–IRES–EGFP (αPIG) vector (Fig. 1A) was linearized
by SacI and 5×106 cellswere electroporatedwith 14 μg of this construct
in Gene Pulser cuvette (0.4 cm electrode, gap 50, BioRad) at 260 V and
500 μF. After neomycin selection, resistant clones were isolated and
propagated. The AT25 clonewas selected based on its high CMdifferen-
tiation efﬁciency.Differentiation to CMs
iPSCs were differentiated in a spinner ﬂask system. Brieﬂy, 1 × 106
undifferentiated cells were suspended in 14 ml of differentiation medi-
um (Iscove's Modiﬁed Dulbecco'sMedium supplementedwith 20% FBS,10 μM β-Mercaptoethanol and 1× non-essential amino acids) and cul-
tured for 2 days in non-adherent plates on a shaker under continuous
agitation to allow formation of EBs. At day 2 of differentiation, the EBs
were counted and diluted into fresh 200 ml medium to a density of
28,000 EBs per spinner ﬂask (Cellspin 250, Integra Biosciences). The dif-
ferentiation process continued for 6–7 days without medium change
until the ﬁrst appearance of green ﬂuorescence in spontaneously beat-
ing EBs. On day 9 of differentiation, fresh medium supplemented with
puromycin (8 μg/ml) was added to purify CMs. After 2–3 days of se-
lection, the surviving cardiac clusters were pooled and further incu-
bated for another 5–6 days on the shaker in fresh medium with
puromycin in non-adherent culture dishes. Fresh medium contain-
ing puromycin was replaced every 2 days until pure beating cardiac
clusters were obtained on day 16 of differentiation after 7 days of
puromycin treatment.
Fig. 3. Expression of cardiac- but not lineage-speciﬁc genes and incomplete silencing of viral Oct4 transgene inαPiG-AT25 iPSC-derived CMs. A. RT-PCR analysis of indicated cardiac (left
panel) and non-cardiac transcripts (right panel) in undifferentiated cells (UD), day 16 EBs and puriﬁed day 16 CMs derived from αPIG44-ESCs or αPiG-AT25-iPSCs. B. RT-PCR analysis of
virally-encoded reprogramming factors in αPIG44-ESCs and αPiG-AT25-iPSCs, their EB counterparts and pure CMs. C. Quantitative real-time PCR analysis of indicated transcripts in
undifferentiated (UD) cells, day 16 EBs and day 16 CMs derived from αPIG44-ESCs or αPiG-AT25-iPSCs.
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Total RNAwas isolated from undifferentiated iPSCs and ESCs, day 16
EBs and day 16 CMs using TRIzol (Invitrogen). DNase I-pretreated RNA
was reverse-transcribed by Superscript II RTase (Invitrogen) using ran-
dom hexamers for priming. The cDNA was ampliﬁed using JumpStart
Red Taq PCR-Ready Mix (Sigma) and the resulting products analyzed
by agarose gel electrophoresis.
Immunocytochemistry
Single CMs were plated on ﬁbronectin-coated μ-dishes (Ibidi) at
0.3 × 106 cells/plate in differentiationmedium containing 8 μg/ml puro-
mycin. After 2–3 days adherent CMs were ﬁxed in 4% bufferedparaformaldehyde (pH 7.5), permeabilized by Triton X-100 and stained
with α-actinin (clone EA-53, 1:400; Sigma), cardiac troponin T (1:200,
Cat. No. sc20025, Santa Cruz) and αMHC (clone A4.1025, 1:100,
Sigma) antibodies. Secondary antibodies were conjugated to
AlexaFluor-555 or AlexaFluor-647 (1:1000, Invitrogen). Nuclei were
stainedwith Hoechst 33,342 (1:5000, Invitrogen) and sampleswere ex-
amined using an Axiovert 200 M ﬂorescence microscope (Zeiss).
Flow cytometry
CMs were prepared by dissociation with 0.05% Trypsin/EDTA. Cell
clumps were removed by passing through the cell strainer, and cells
were analyzed by ﬂow cytometry (FACScan, BD Pharmingen).
Propidium iodide was used for dead cell staining. For intracellular
Fig. 4. Current-clamp characterization of murine αPiG-AT25 iPSC-derived CMs. A. The atrial-like, pacemaker-like and ventricular-like AP traces of single iPSC-derived CMs. 6 out of 16
measured APs (37.5%) could not be deﬁnitively categorized. B. Representative AP recording traces showing the effect of isoproterenol (Iso, 1 μM) and carbachol (CCh, 1 μM) on drug
selected iPSC-CMs. Comparison of the effect of Iso and CCh on the spontaneous AP frequency (C) and the AP duration at 90% repolarization (APD90) (D) in αPiG-AT25-iPSC- and
αPiG44-ESC-derived CMs.
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with 1% saponin (Sigma-Aldrich) in 5% BSA diluted in PBS for 1 h at
room temperature before incubatingwith 1:50 dilutedmonoclonal mu-
rine anti-cTnT antibody in 1% Saponin and 0.8% BSA in PBS for 30min at
4 °C. The secondary anti-mouse antibody (Alexa-Fluor 555 labeled, Mo-
lecular Probes)was diluted 1:100 in 1% Saponin and 0.8%BSA in PBS and
incubated for 1 h at 4 °C.
Electrophysiology
For patch-clamp experiments, puromycin-puriﬁed cardiac clusters
were dissociated into single CMsby using collagenase B on day 14 of dif-
ferentiation and then plated on 0.1% gelatin-coated 22 × 22mm square
glass cover slips in 3.5 cm dishes. Cells were incubated for 24–48 h be-
fore measurements were performed. Individual CMs were selected ac-
cording to their typical morphology and spontaneous beating activity.
The glass cover slips containing the cells were placed into a tempera-
ture-controlled (37 °C) recording chamber and perfused continuously
with extracellular solution. Cell membrane capacitancewas determined
on-line using the Pulse program (Heka Elektronik). APs of spontaneous-
ly beating CMs were recorded by the whole-cell current-clamp tech-
nique using an EPC-9 ampliﬁer and operated through the PULSE
acquisition software (HEKAElektronik, Lambrecht, Germany). Responseof CMs to hormonal regulation was assessed by administering isopro-
terenol (Iso) and carbachol (CCh) (Sigma-Aldrich). The standard
whole-cell patch-clamp recording technique (Hamill et al., 1981) in
the voltage-clamp mode was used for recording voltage-gated Na+-,
L-type Ca2+-, and depolarization-activated outward K+-channel
currents.
For recording Na+ and L-type Ca2+ currents, extracellular solution
contained (in mM): NaCl 120, KCl 5, CaCl2 3.6, MgCl2 1,
tetraethylammonium (TEA) chloride 20, HEPES 10, pH adjusted to
7.40 at 37 °C with TEA-OH. For recording K+ currents, extra cellular so-
lution contained (in mM): N-methyl-D-glucamine (NMG) chloride 135,
KCl 5, CaCl2 3.6, MgCl2 1, NiCl2 3, HEPES 10, pH adjusted to 7.40 at 37 °C
with NMG. Intracellular solutions contained: for Na+ and Ca2+ currents
(in mM) – CsCl 120, MgCl2 3, MgATP 5, EGTA 10, HEPES 5, pH adjusted
to 7.40 with CsOH; and for K+ current recordings (in mM) – KCl 50, K-
aspartate 80, MgCl2 1,MgATP 3, EGTA 10, HEPES 10, pH adjusted to 7.40
with NMG. If not stated otherwise, all reagents were obtained from
Sigma-Aldrich Chemie GmbH, Germany.
Na+ channel currents were elicited by a family of 100-ms depolar-
izations from a − 90 mV holding potential (HP) to voltages ranging
from−60 to+55mV in 5-mV steps. Ca2+ channel currents weremea-
sured with a double-pulse protocol. First, a 100-ms depolarization from
a HP of−90 mV to−40 mV was applied to inactivate Na+ and T-type
Fig. 5. Functional voltage-gated ion channels in iPSC-derived CMs. A. Current densities of Na+, L-type Ca2+ and different depolarization-activated outward K+ channels (fast activating
currents, comprising Ipeak, and slow activating currents remaining at the end of depolarization, comprising Isus) were determined in αPiG-AT25-iPSC- and αPiG44-ESC-derived CMs
using the whole-cell voltage-clamp. B. Na+ channel currents in iPSC-derived CMs were elicited by a family of 100-ms depolarizations from a −90 mV holding potential (HP) to
voltages ranging from−60 to +55 mV in 5-mV steps. C. Ca2+ channel currents in iPSC-derived CMs were measured with a double-pulse protocol. First, a 100-ms depolarization from
a HP of −90 mV to −40 mV was applied to inactivate Na+ and T-type Ca2+ channels, then L-type Ca2+ channels were elicited by a family of 67-ms depolarizations to voltages
ranging from−60 to +50 mV in 10-mV steps. In Na+ and Ca2+ channel experiments, leak subtraction -P/4 protocol was applied from HP of−90 mV. D. Depolarization-activated
outward K+ currents in iPSC-derived CMs were elicited by a family of 500-ms depolarizations from a−80 mV HP to voltages ranging from−40 mV to +60 mV in 10 mV steps. We
analyzed peak current values (Ipeak) and sustained currents (Isus, remaining currents at the end of depolarization). Leak and capacity transients were eliminated by 4 pulses P/10 from
a−80 mV HP. In ﬁgure inlays in panels B-D amplitudes of a corresponding current normalized to a cell size (current density values, in pA/pF) are plotted against test voltages (in
mV). In panel D, squares represent Ipeak and circles represent Isus density values. E. Current-voltage relationships of Na+, L-type Ca2+, Ipeak, and Isus currents in puromycin selected iPS-
and ES-CMs. Current amplitudes are normalized to a maximum and are plotted against test voltages (in mV). The number of cells used in voltage-clamp experiments range from n =
15 to n = 43. None of the values were statistically signiﬁcantly different between transgenic iPSC- and ESC-derived CMs.
271A. Fatima et al. / Stem Cell Research 17 (2016) 266–272Ca2+ channels, then L-type Ca2+ channels were elicited by a family of
67-ms depolarizations to voltages ranging from −60 to +50 mV in
10-mV steps. In Na+ and Ca2+ channel experiments, leak subtraction
-P/4 protocolwas applied fromHPof−90mV. Depolarization-activated
outward K+ currents were elicited by a family of 500-ms depolariza-
tions from a − 80 mV HP to voltages ranging from −40 mV to
+60 mV in 10 mV steps. We analyzed peak current values (Ipeak) and
sustained currents (Isus, remaining currents at the end of depolariza-
tion). Leak and capacity transients were eliminated by 4 pulses P/10
from a−80 mV HP.
The data on L-type Ca2+ currents and Na+ currents was collected si-
multaneously. There was no contamination of L-type Ca2+ currents
with Na+, as those were fully inactivated with a long conditioning
pre-pulse to−40 mV, before L-type Ca2+ currents were elicited by a
test pulse. L-type currents were also always checked for the presenceof fast activation component suggesting a contamination with Na+ cur-
rent, but there was no such component visible. L-type Ca2+ channels
were not affected by the pre-pulse, as they activate in a more positive
voltage range. Additionally, the Ca2+ current contamination in Na+ cur-
rents was also estimated. As L-type currents were always co-measured
in the cells where Na+ channel currents were recorded, we compared
the amplitudes. If the maxima at corresponding potentials are com-
pared, the mean contamination of Na+ currents with an L-type current
is b1%, in the most relevant voltage range (from−50 to−10 mV) it is
b0.5%. Considering that the activation of L-type Ca2+ channels is 5–10
times slower than the Na+ channel activation, we estimate the L-type
current contribution to b0.1%. Thus, the tiny Ca2+ current contamina-
tion in the Na+ currents could be neglected.
Data are presented as themean±standard error of themean (SEM).
Student's t-test was applied for statistical evaluation.
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